Should I buy Ligand Pharmaceuticals, Inc. (LGND) stock or is it too late?

Ligand Pharmaceuticals, Inc. · Health Care · price $304

See the full Ligand Pharmaceuticals, Inc. (LGND) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Leerink Partners — 64% of its targets hit on this sector (11 calls tested). It aims for $330 (+8.7 %), call made on August 15, 2026, maturing on August 15, 2027 (60 d ago).

The 2 reliable analysts $344+13 %

The 6 other firms $345+14 %

How to read it: the 2 reliable firms are not filtered by optimism — 2 aim above the price, 0 below, hence their $344 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Ligand Pharmaceuticals, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Oppenheimer	100 %	+90.5 %	6	$326 +7%
RBC Capital	100 %	+61.3 %	6	$345 +14%
Benchmark	100 %	+54.8 %	11	$220 -28%
HC Wainwright & Co.	80 %	+30.8 %	20	$358 +18%
Barclays	46 %	+8.6 %	13	$345 +14%
Roth Capital	71 %	+3.2 %	7	—

In short — Should you invest in Ligand Pharmaceuticals, Inc.? Is it too late, still worth it? Analysts are overwhelmingly positive (100% buy, median target $345, i.e. +14%), and the most reliable on LGND targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

100% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
Median price target $345, i.e. +14% from the current price ($304).
The most reliable firm on LGND, Oppenheimer (100% hit rate, 6 scored calls), targets $326 (call made on August 3, 2026, maturing on August 3, 2027) (+7%) in its most recent call, and $250 (call made on November 3, 2025, maturing on November 3, 2026) (-18%) in the one coming due soonest.

⚠️ Reasons to hesitate

A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.
A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.

The analyst consensus on LGND

Median target $345 (+14%) · 8 ratings · Buy consensus

Strong Buy00%

Buy8100%

Hold00%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Ligand Pharmaceuticals, Inc. now?

We won't decide for you. The facts: 100% of analysts rate it a buy, median target $345 (+14%), and Oppenheimer (most reliable on LGND, 100%) targets $326. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Ligand Pharmaceuticals, Inc.?

Not according to analysts: the median target ($345) is still +14% above the current price ($304) (most reliable on LGND: Oppenheimer, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Ligand Pharmaceuticals, Inc. still worth investing in?

It depends on the gap between the price ($304) and its estimated value: analysts target $345 on median (+14%), with 100% buys (most reliable on LGND: Oppenheimer, 100%). Cross-check with their real reliability on LGND and the cautions above. Information, not advice.

What's the main risk in buying LGND?

A 12-month target is not a guaranteed path: the price can fall in the meantime.

→ Go deeper: the full Ligand Pharmaceuticals, Inc. profile (consensus, analyst reliability, price target, performance).